Precigen, INC.: insider trades · United States · SEC (Form 4)

About Precigen, INC.

Precigen, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker PGEN, with headquarters in Germantown, Maryland, United States. The company originated from Intrexon and has since repositioned itself around precision medicines aimed at difficult-to-treat diseases with high unmet medical need. Its core business is centered on the discovery, development, and commercialization of advanced gene and cell therapy-based products, using proprietary technology designed to address complex biological targets. For international investors, the most important element of the current equity story is Precigen’s transition from a research-heavy developer into a commercial-stage biopharma company. That shift was driven by the U.S. FDA approval of PAPZIMEOS (zopapogene imadenovec-drba) for adults with recurrent respiratory papillomatosis, or RRP. Recent company communications describe PAPZIMEOS as the first and only FDA-approved therapy for this indication, which gives Precigen a differentiated position in a rare disease niche with significant clinical unmet need. While the company still maintains broader scientific ambitions across immuno-oncology, autoimmune disorders, and infectious diseases, near-term value creation is primarily tied to the commercial rollout of PAPZIMEOS. From a competitive standpoint, Precigen is best viewed as a specialized small-cap biotech rather than a scaled pharmaceutical platform. Its moat is based on scientific differentiation, regulatory exclusivity around its lead asset, and the rarity of the disease area it serves. The company does not compete on breadth of portfolio in the way large-cap pharma does; instead, its investment case depends on clinical credibility, physician adoption, and the ability to translate a novel therapy into sustainable commercial traction. Because it is listed in the United States on NASDAQ, the stock is closely followed by global healthcare investors looking for asymmetric biotech opportunities. Recent milestones have been material. In August 2025, Precigen received full FDA approval for PAPZIMEOS, and in 2026 the company highlighted expert consensus support and long-term follow-up data that reinforced durable clinical responses. The company has also communicated rapid commercialization momentum in early 2026. Overall, Precigen represents a high-impact healthcare story: a U.S. NASDAQ-listed innovator with one flagship approved product, a clear rare-disease niche, and meaningful execution risk and upside tied to commercial adoption and pipeline progress.